6 trends tracked about this subject — the full history, oldest to newest below.
Sanofi and Regeneron have deepened their immunology alliance in a deal worth up to $8 billion to secure early-stage assets and a Dupixent successor.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Kodiak stock surges after a Phase III clinical victory for its Eylea rival targeting wet AMD.
Kodiak Sciences shares surged over 90% following positive Phase 3 trial results for an eye disease drug targeting AMD.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.